National Center for Immunization & Respiratory Diseases

Influenza Work Group—Introduction

Dr. Jamie Loehr (Work Group Chair)

Advisory Committee on Immunization Practices

October 25, 2023
Influenza Work Group

ACIP Members

• Jamie Loehr (Chair)

• Keipp Talbot 

• Camille Kotton

Ex Officio

• Timothy Brennan (FDA)

• Uzo Chukwuma (IHS)

• Jeffrey Kelman (CMS)

• Valerie Marshall (OASH)

• Cynthia Nolletti (FDA)

• Chris Roberts (NIH)

Liaison Representatives and Consultants

• Robert Atmar

• Kevin Ault

• Ed Belongia

• Hank Bernstein

• Thomas Boyce

• Kris Bryant

• Doug Campos-Outcalt

• Sarah Coles

• Frances Ferguson

• Alicia Fry

• Sandra Fryhofer

• Wendy Keitel

• Marie-Michèle Léger

• Susan Lett

• Krissy Moehling

• Zackary Moore

• Rebecca Morgan

• Kathy Neuzil

• Jesse Papenburg

• William Schaffner

• Rob Schechter 

• Ken Schmader 

• Tamara Sheffield

• Angela Sinilaite

• Patsy Stinchfield 

• Peter Szilagyi

• Matthew Zahn

CDC Lead

• Lisa Grohskopf

2
CDC Participants • Lenee Blanton • Karen Broder • Alicia Budd • Jessie Chung • Sascha Ellington • Jill Ferdinands • Brendan Flannery • Andrew Kroger • Samantha Olson • David Shay • Tom Shimabukuro • Mark Tenforde • Tim Uyeki

3
Influenza Vaccines in Pregnancy

Updates:

• Safety of Quadrivalent Recombinant Influenza Vaccine in Pregnant Women and their Infants—

Dr. Nicky Klein (Kaiser Permanente Northern California)

• Pregnancy Outcomes with ccIIV4 (Flucelvax); Post Marketing Study—Dr. Gregg Sylvester (Seqirus)

• Effectiveness of Maternal Influenza Vaccination during Pregnancy Against Influenza-associated 

Hospitalizations & ED Visits in Infants <6 Months of Age—Ms. Samantha Olson (CDC/NCIRD) 

− To be presented tomorrow

Issues:

• Influenza vaccination recommended for pregnant persons

• While there is considerable experience with safe administration of influenza vaccines in 

pregnancy, there are fewer data specific to newer influenza vaccine formulations

4
Co-administration of Vaccines in Adults

Updates:

• Safety of Simultaneous versus Sequential Administration of mRNA COVID-19 and Quadrivalent 

Inactivated Influenza (IIV4) Vaccines—Dr. Emmanuel “Chip” Walter (Duke University)

• Safety of Simultaneous Vaccination with Zoster Vaccine Recombinant (RZV) and Quadrivalent 

Adjuvanted Inactivated Influenza Vaccine (allV4)—Dr. Kenneth Schmader (Duke University)

• Update on COVID-19 and Influenza Vaccine Safety—Dr. Tom Shimabukuro (CDC/NCIRD)

Issues:

• Simultaneous administration or co-administration of all vaccines for which a recipient is due is a 

generally recommended practice for most combinations of vaccines

• Specific data for co-administration of many combinations involving newer vaccines are limited

• Data on co-administration of two or more vaccines with newer adjuvants are limited

5
Influenza B/Yamagata Surveillance

Update:

• Update on Influenza B/Yamagata Surveillance—Dr. Rebecca Kondor (CDC/NCIRD) 

− To be presented tomorrow

Issues:

• All current U.S. influenza vaccines are quadrivalent—they contain antigen from 4 influenza 

viruses, including an A(H1N1) virus, an A(H3N2) virus, and 2 influenza B viruses (one from each 

of two B lineages)

• Quadrivalent influenza vaccines were initially introduced in 2013-14, to permit broader coverage 

of potentially circulating influenza B viruses (previous trivalent vaccines contained one influenza 

B virus from one lineage)

• There have been no confirmed detections of influenza B/Yamagata lineage viruses in global 

surveillance since March 2020, leading to discussion by WHO and FDA of their continued 

inclusion in influenza vaccines

6
For more information, contact CDC

1-800-CDC-INFO (232-4636)

TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the 

official position of the Centers for Disease Control and Prevention.